InsiderSignal.AI

InsiderSignal.ai

TRDA - Entrada Therapeutics, Inc.

Insider Sale by Wentworth Kory James (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Wentworth Kory James, serving as CFO at Entrada Therapeutics, Inc. (TRDA), sold 2,500 shares at $12.95 per share, for a total transaction value of $32,375.00. Following this transaction, Wentworth Kory James now holds 119,010 shares of TRDA.

This sale represents a 2.00% decrease in Wentworth Kory James's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 1 day after the trade was made.

Entrada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Wentworth Kory James

CFO

Kory James Wentworth is the Chief Financial Officer and Treasurer of Entrada Therapeutics, Inc. (NASDAQ: TRDA), a clinical-stage biotechnology company developing intracellular biologics using its proprietary cell-penetrating miniature protein (CPMP) platform.[[1]](https://theorg.com/org/entrada-therapeutics/org-chart/kory-wentworth)[[2]](https://www.marketbeat.com/instant-alerts/entrada-therapeutics-nasdaqtrda-cfo-kory-james-wentworth-sells-5089-shares-2026-03-11/) A Certified Public Accountant (CPA) in Connecticut, he holds a BS in Accounting from Susquehanna University.[[1]](https://theorg.com/org/entrada-therapeutics/org-chart/kory-wentworth) Wentworth's career includes prior roles as VP Finance and Treasurer, Principal Accounting Officer at bluebird bio, where he managed accounting, tax, treasury, finance operations, and reporting, building a global team for expansion and product launches.[[1]](https://theorg.com/org/entrada-therapeutics/org-chart/kory-wentworth) Before that, he spent nine years at Alexion Pharmaceuticals, rising to Executive Director and Corporate Controller, and earlier held audit positions at PricewaterhouseCoopers LLP for six years.[[1]](https://theorg.com/org/entrada-therapeutics/org-chart/kory-wentworth) Recently, as Entrada CFO, he sold shares in multiple transactions in early March 2026, totaling 24,465 shares for approximately $312,000, retaining 132,898 shares valued at about $1.73 million.[[2]](https://www.marketbeat.com/instant-alerts/entrada-therapeutics-nasdaqtrda-cfo-kory-james-wentworth-sells-5089-shares-2026-03-11/)

View full insider profile →

Trade Price

$12.95

Quantity

2,500

Total Value

$32,375.00

Shares Owned

119,010

Trade Date

Wednesday, April 1, 2026

4 days ago

SEC Filing Date

Thursday, April 2, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Entrada Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TRDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5311559

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime